Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138559 | 1.00 | MME (0.42) | MMECTSKCTSSCTSLFOLH1 | |
| SCHEMBL7130607 | 0.89 | SMN1; SMN2 (0.42) | CTSKCTSLCTSB | |
| SCHEMBL7137505 | 0.85 | SMN1; SMN2 (0.41) | CTSKCTSLCTSB | |
| SCHEMBL7133729 | 0.83 | SMN1; SMN2 (0.42) | CTSKCTSLCTSB | |
| SCHEMBL7137549 | 0.82 | CASP1 (0.43) | CTSKCTSLCTSB | |
| SCHEMBL7139203 | 0.80 | NMBR (0.59) | MMEMMP9MMP14 | |
| SCHEMBL7136764 | 0.78 | SMN1; SMN2 (0.42) | CTSKCTSLCTSB | |
| SCHEMBL6183201 | 0.78 | CTSL (0.44) | CTSKCTSSCTSLCTSB | |
| SCHEMBL7136801 | 0.78 | SMN1; SMN2 (0.44) | CTSKCTSSCTSLFOLH1CTSB | |
| SCHEMBL6181961 | 0.76 | CTSC (0.49) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | MME 16/4885CTSK 29/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.